SCA
TEVA icon

Salient Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Salient Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,500
Closed -$276K – 253
2016
Q2 		$276K Buy
5,500
+744
+16% +$39.6K 0.01% 216
2016
Q1 		$254K Buy
+4,756
New +$279K 0.01% 216

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Salient Capital Advisors's TEVA Position: Q3 2016 in Review

Salient Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 5,500 shares — an estimated $276K sold.

Salient Capital Advisors first reported a position in TEVA in Q1 2016 and held it in 2 quarters. The position peaked at $276K in Q2 2016. 798 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Salient Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Salient Capital Advisors sold 5,500 Teva Pharmaceuticals shares in Q3 2016, an estimated $276K.
  • Salient Capital Advisors first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Salient Capital Advisors's Teva Pharmaceuticals position peaked at $276K in Q2 2016.
  • 798 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Salient Capital Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.